NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Petty D, Lloyd D. Can cheap generic statins achieve national cholesterol lowering targets? J Health Serv Res Policy 2008;13:99–102 Primary Care Trusts (PCTs) with a high proportion of simvastatin […]
Category Archives: Cardiovascular disease
NPC Archive Item: Aspirin ineffective for primary prevention in patients with diabetes
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in […]
NPC Archive Item: SEAS and ezetimibe▼: no benefits on CV endpoints, questions raised over cancer risk
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Rossebø AB, et al for the SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359 (early online publication, September 2nd […]
NPC Archive Item: Omega-3 polyunsaturated fatty acids, but not rosuvastatin, may provide a benefit in heart failure
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. GISSI-HF investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (early online publication) 31 August 2008; […]
NPC Archive Item: ARBs as effective as ACE inhibitors in CV risk reduction? — Jury still out.
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Effects of angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Results from a large randomised controlled trial (TRANSCEND) question […]
NPC Archive Item: Clopidogrel and aspirin + dipyridamole similarly effective in secondary prevention of stroke
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Sacco RL et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. New Engl J Med 2008; 359 (published on line 27th August 2008) This study has a […]
NPC Archive Item: Rivaroxaban for prevention of venous thromboembolism in patients undergoing total hip or knee replacement
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Eriksson BI, Borris LC, Friedman RJ et al. Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty. N Engl J Med 2008; 358:2765-75 Kakkar AK, Brenner B, Dahl OE […]
NPC Archive Item: QRISK2 – a valid tool for predicting cardiovascular risk?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336;1475–82 QRISK2 may provide a more accurate […]
NPC Archive Item: NICE highlights NPC patient decision aid in its lipid guidance
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. NICE Clinical Guideline 67: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease Patients should be given information about their […]
NPC Archive Item: NICE publishes guidance on CV risk assessment and lipid modification
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. NICE Clinical Guideline 67: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease NICE recommends using simvastatin 40 mg as […]